Therapeutic options for the management of hepatitis C virus (HCV) infection have evolved rapidly over the past two decades, with a consequent improvement in cure rates.
Novel therapeutic agents are an area of great interest in the research community, with a number of these agents showing promise in the clinical setting.
Dr Miller and colleagues from the United Kingdom assessed and presented the available evidence for the use of novel therapeutic agents for the treatment of HCV, updating previous guidelines.
All Phase 2 and 3 studies, as well as abstract presentations from international Hepatology meetings were identified and reviewed for suitable inclusion, based on studies of new therapies in HCV.
|Precise regimens are largely dependent on the patient characteristics|
|Alimentary Pharmacology & Therapeutics|
Treatment-naïve and experienced individuals, as well as cirrhotic and co-infected individuals were included.
The team observed that sofosbuvir, simeprevir and faldaprevir, along with pegylated interferon and ribavirin, have a role in the treatment of chronic HCV infection.
The team noted that the precise regimens are largely dependent on the patient characteristics, patient and physician preferences, and cost implication.
Dr Miller's team concludes, "Therapies for chronic HCV have evolved dramatically in recent years. Interferon-free regimens are now possible without compromise in the rate of sustained viral response."
"The decision as to which regimen is most appropriate is multifactorial, and based on efficacy, safety and cost."